{
    "clinical_study": {
        "@rank": "102506", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Adding eatable flour into the pills"
            }, 
            {
                "arm_group_label": "Doxycycline treatment", 
                "arm_group_type": "Experimental", 
                "description": "Doxycycline treatment 50mg bid x 14 days then 50mg qd x 10 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of oral low dose doxycycline in the treatment of corneal\n      burn."
        }, 
        "brief_title": "Low Dose Doxycycline in the Treatment of Corneal Burn", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Eye Burns", 
        "condition_browse": {
            "mesh_term": [
                "Burns", 
                "Eye Burns"
            ]
        }, 
        "detailed_description": {
            "textblock": "Severe Ocular Burn often leads to the Ocular surface failure, corneal vascularization\n      dissolved hole or corneal opacity.Because the conventional treatment effect is not ideal,\n      blindness rate is extremely high, has been a very challenging catastrophic ophthalmic\n      emergency.Early effective inhibition of inflammation, promote healing of corneal epithelium\n      is the key of reducing corneal perforation, corneal neovascularization, improving corneal\n      transparency.Existing anti-inflammatory treatment including the hormone and immune\n      inhibitors, auto-serum, non-steroidal anti-inflammatory drugs, amniotic membrane\n      transplantation or amniotic membrane patch, etc.Although these measures have some effect,\n      they have their disadvantages.Select both broad-spectrum anti-inflammatory effects and\n      moderate price, good safety anti-inflammatory drugs is particularly important.\n\n      Sub-antimicrobial dose doxycycline posses known anti-inflammatory effects that are separate\n      from their antibacterial mode of action.This mode of action has lead to the routine use of\n      sub-antimicrobial dose doxycycline for treating inflammatory or autoimmune diseases, such as\n      rosacea, periodontitis and multiple sclerosis.We confirmed on the basis of predecessors'\n      studies that low dose oral doxycycline and topical application of doxycycline can accelerate\n      corneal epithelium healing after ocular surface burn, effectively inhibit inflammation\n      mediated corneal new angiogenesis.Its mechanism of action is about downregulate  MMP2 and\n      nitric oxide synthase.\n\n      Given the previous research obtained the encouraging result, we plan to carry out a clinical\n      research, to explore oral low-dose doxycycline efficacy and safety of the treatment of\n      corneal burns."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1.age from 18-70 years old, not limited to sex\n\n             2. ocular burn (including chemical injury, thermal burns)\n\n             3. studies of eye with Dua grade (2001) III, within 14 days after burns\n\n             4. about the eye burns\n\n               1. become the research with only one eye\n\n               2. conform to the standards of subjects for the eyes\n\n        Choose poor eyesight as in the study\n\n        If the vision is the same on both sides, the choice classification is higher as the\n        research of eye\n\n        If the binocular vision and graded at the same time, according to a study in can be\n        determined in consultation with the patient's eye\n\n        5.signed informed consent form\n\n        Exclusion Criteria:\n\n        - 1. Only one eye function\n\n        2.The exclusion criteria of the eye\n\n        A) corneal thinning depth \u2265 1/2CT, corneal perforation or perforation tendency\n\n        B, Dua classification I\u3001II\u3001IV\u3001V\u3001VI\n\n        C) after injury had received eye operation (such as amniotic membrane transplantation or\n        covering)\n\n        D) Poor control of intraocular pressure after anti-glaucoma drug treatment (IOP \u2265 25mmHg)\n\n        E) past other corneal diseases\n\n        F) past ocular history of radiation therapy or eye operation history\n\n        G) eyelid defect, incomplete eyelid closure, entropion, trichiasis\n\n        3. Any side formulated after secondary infection\n\n        4. Other rule out criteria\n\n        A) Tetracycline class history of drug allergy\n\n        B) poor control of blood pressure (defined as after treatment with antihypertensive drugs,\n        blood pressure is 150/95mmHg or higher)\n\n        C) serious heart, hepatic, renal insufficiency (or myocardial infarction, arrhythmia,\n        myocardial ischemia and cardiac insufficiency, ALT, AST, upper limit of normal or higher\n        by 2.5 times, creatinine upper limit of normal or higher by 1.5 times)\n\n        D) during pregnancy or lactation women (defined as pregnancy urine pregnancy test results\n        in this test)\n\n        E) child-bearing age subjects (male and female) is suitable precautions during the entire\n        study\n\n        F) into the group participated in other clinical subjects before 3 months\n\n        G) people with TB\n\n        H) nerve with mental illness"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01886560", 
            "org_study_id": "SunYat-senU2"
        }, 
        "intervention": [
            {
                "arm_group_label": "Doxycycline treatment", 
                "description": "Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.", 
                "intervention_name": "Doxycycline", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Dolotard", 
                    "Tibirox", 
                    "Biomycin"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Tablets placebo one PO per day for 12 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "dummy"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 7, 2013", 
        "location": {
            "contact": {
                "email": "liangd2@mail.sysu.edu.cn", 
                "last_name": "Dan Liang, MD", 
                "phone": "0086-20-87331766"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Zhongshan Ophthalmic Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Double-blind, Randomized, Controlled Clinical Trial of Low Dose Doxycycline in the Treatment of Corneal Burn", 
        "overall_contact": {
            "email": "liangd2@mail.sysu.edu.cn", 
            "last_name": "Dan Liang, MD", 
            "phone": "0086-20-87331766"
        }, 
        "overall_contact_backup": {
            "email": "shoouzhang35@sina.com", 
            "last_name": "Jingwen Huang", 
            "phone": "0086-20-87331541"
        }, 
        "overall_official": {
            "affiliation": "Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China", 
            "last_name": "Dan Liang, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "China: Food and Drug Administration", 
                "China: Ethics Committee"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time for Corneal epithelialization after treatment", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01886560"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Dan Liang", 
            "investigator_title": "Zhongshan Ophthalmic Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "corneal limbal ischemia", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Safety and tolerability as assessed by adverse events, vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "corneal neovascularization", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Corneal transparency", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "cornea ulcer with perforation", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}